Sanofi Puts Up $1B to Expand Regeneron Alliance and Develop Next-Gen Dupixent

T2Covered by 1 source · first reported by Fierce Biotech / Fierce Healthcare / MedCity / GEN at 01 Oct, 20:13 UTC

Sanofi and Regeneron Pharmaceuticals will collaborate on four next-generation antibody drugs that could offer advantages over Dupixent, the blockbuster immunology drug spawned by their R&D alliance. The companies project these drugs will start reaching pivotal testing in 2029 — important because…

science

Sources

• T2Sanofi Puts Up $1B to Expand Regeneron Alliance and Develop Next-Gen DupixentFierce Biotech / Fierce Healthcare / MedCity / GEN01 Oct, 20:13